The equity financing was led by Sibel's existing investors, the Steele Foundation for Hope and Dräger, to accelerate commercial deployment of the ANNE® One monitoring platform. The Steele Foundation for Hope previously led Sibel's Series B round, adding an additional $20 million investment. Dräger, an international leader in medical and safety technology, previously led Sibel's Series A round, contributing $10 million more in funding..

股权融资由Sibel的现有投资者 Steele Foundation for Hope 和 Dräger 领投，以加速ANNE® One监测平台的商业部署。Steele Foundation for Hope 此前领投了Sibel的B轮融资，追加了2000万美元的投资。Dräger作为医疗和安全技术的国际领导者，此前领投了Sibel的A轮融资，额外贡献了1000万美元的资金。

Sibel Health is an award-winning medical technology company with a mission to deliver Better Health Data for All®. Based in Chicago with an international office in Seoul, South Korea, Sibel Health is a leading provider of advanced monitoring solutions for patients of all ages in the home or hospital.

Sibel Health是一家屡获殊荣的医疗技术公司，致力于实现“为所有人提供更好的健康数据®”的使命。公司总部位于芝加哥，并在韩国首尔设有国际办公室，是为各年龄段患者提供先进监测解决方案的领先供应商，适用于家庭或医院环境。

In addition, Sibel Health offers novel digital health technologies for the pharmaceutical and clinical research markets..

此外，Sibel Health 还为制药和临床研究市场提供新颖的数字健康技术。